Q-omics provides the consensus-scored RPL35P1 profile across patient tissues and cancer cell-line models. RPL35P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL35P1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, RPL35P1 RNA expression shows 17,243 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, KIRC, and DLBC as cancer lineages where RPL35P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL35P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL35P1 survival associations across molecular data types. RPL35P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL35P1 RNA expression–survival associations across cancer types. High RPL35P1 expression shows unfavorable associations in ACC, LIHC, KIRP, UCS and KICH, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL35P1 RNA expression.
This table summarizes RPL35P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL35P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL35P1 shows lower tumor expression in BRCA and higher tumor expression in KIRC, KIRP, LUSC, LIHC and HNSC. The KIRC box plot shows higher RPL35P1 RNA expression in tumor versus normal tissue (log2 FC = +0.955, t-test p < 0.001).
This table shows molecular features associated with RPL35P1 in patient tissues and cancer cell lines. In patient samples, RPL35P1 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
